Glenmark Pharmaceuticals Limited Stock

Equities

GLENMARK

INE935A01035

Pharmaceuticals

Market Closed - NSE India S.E. 07:40:30 2024-05-08 am EDT 5-day change 1st Jan Change
1,022 INR +0.57% Intraday chart for Glenmark Pharmaceuticals Limited -3.68% +19.62%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 121B 1.45B Sales 2025 * 140B 1.68B Capitalization 287B 3.43B
Net income 2024 * 33.36B 400M Net income 2025 * 11.13B 133M EV / Sales 2024 * 2.52 x
Net Debt 2024 * 19.84B 238M Net cash position 2025 * 3.08B 36.9M EV / Sales 2025 * 2.02 x
P/E ratio 2024 *
40.1 x
P/E ratio 2025 *
23.6 x
Employees 15,556
Yield 2024 *
0.23%
Yield 2025 *
0.28%
Free-Float 49.03%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Glenmark Pharmaceuticals Limited

1 day+0.91%
1 week-3.35%
Current month-3.05%
1 month-1.36%
3 months+19.39%
6 months+30.42%
Current year+20.03%
More quotes
1 week
997.80
Extreme 997.8
1 071.30
1 month
997.80
Extreme 997.8
1 098.00
Current year
771.00
Extreme 771
1 098.00
1 year
557.40
Extreme 557.4
1 098.00
3 years
348.50
Extreme 348.5
1 098.00
5 years
161.65
Extreme 161.65
1 098.00
10 years
161.65
Extreme 161.65
1 262.90
More quotes
Managers TitleAgeSince
Founder - -
Chief Executive Officer 54 98-10-11
President - -
Members of the board TitleAgeSince
Director/Board Member 59 20-08-13
Director/Board Member 56 99-10-05
Chief Executive Officer 54 98-10-11
More insiders
Date Price Change Volume
24-05-08 1,022 +0.57% 213 896
24-05-07 1,016 -2.39% 560,484
24-05-06 1,041 -1.20% 414,896
24-05-03 1,053 -0.68% 845,271
24-05-02 1,060 +0.31% 324,107

Delayed Quote NSE India S.E., May 08, 2024 at 03:21 am EDT

More quotes
Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
1,016 INR
Average target price
962.8 INR
Spread / Average Target
-5.21%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. GLENMARK Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW